Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonistsElectronic supplementary information (ESI) available: Fig. S1: behaviors of TF14013, TF14016 and TF14013-Me in mouse serum; Fig. S2: behaviors of TF14002 (a), TF14005 (b), TF14006 (c), TF14013 (d), TF14016 (e) and TF14013 analogs (f) in rat liver homogenate; Table S1: characterization data of novel synthetic peptides; and HPLC charts for synthetic compounds of 4F-benzoyl-TE14011 (TF14013), 4F-benzoyl-TN14003 (TF14016), nicotinoyl-TE14011 (TF14031) and 4F-benzoyl-TE14011-Me (TF14013-Me), and for a degraded sample of 4F-benzoyl-TE14011 (TF14013) in rat liver homogenate and its co-injection with an authentic compound des-[Arg14-NH2]-4F-benzoyl-TE14011. See http://www.rsc.org/suppdata/ob/b3/b306613b/